Overview

Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study aims to study the efficacy (as measured by change in FEV1) and safety of two-week administration of oral QAV680 in the treatment of patients with asthma.'
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Fluticasone
Xhance